TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01593046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 Oral
Description: 30mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 800mg intramuscular injection
Description: 800mg Loading dose given at month 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 800mg intramuscular injection
Description: 800mg Loading dose given at month 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 800mg intramuscular injection
Description: 800mg Loading dose given at month 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 200mg subcutaneous injection
Description: 200mg maintenance dose give at months 2 - 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 200mg intramuscular injection
Description: 200mg maintenance dose given at months 2 - 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 400mg intramuscular injection
Description: 400mg maintenance dose given at month 2 - 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 LA 1200mg intramuscular injection
Description: 1200mg Loading dose given at month 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 LA 1200mg intramuscular injection
Description: 1200mg Loading dose given at month 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 LA 600mg intramuscular injection
Description: 600mg Loading dose given at month 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278 LA 600mg intramuscular injection
Description: 600mg Loading dose given at month 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 LAP 800mg intramuscular injection
Description: 800mg dose given quarterly (once every) 12 weeks
Study: NCT00182793

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy.
Study: NCT02825589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIA
Description: BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
Study: NCT00694239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge of Cardiovascular Risk Assessment
Description: Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
Study: NCT02330731

Intervention type: PROCEDURE
Group type: OTHER
Intervention: injection sclerotherapy for gastric varices
Description: The intravariceal technique of injection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: injection sclerotherapy for gastric varices
Description: The intravariceal technique of injection
Study: NCT04130243

Intervention type: OTHER
Intervention: Blood test
Description: Withdrawal of (extra) blood to measure serum biomarkers with a blood test

Intervention type: OTHER
Intervention: Blood test
Description: Withdrawal of (extra) blood to measure serum biomarkers with a blood test
Study: NCT00727753

Intervention type: DRUG
Intervention: Ranibizumab
Description: ranibizumab (0.5 mg) will be injected intraocular
Study: NCT01044108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0453
Description: Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
Study: NCT00727753

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab (1.25 mg) will be injected intraocular

Intervention type: OTHER
Intervention: No treatment
Description: No treatment
Study: NCT03429179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
Study: NCT02330731

Intervention type: PROCEDURE
Group type: OTHER
Intervention: injection sclerotherapy for gastric varices
Description: The intravariceal technique of injection
Study: NCT01180829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback text messages
Description: A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consciousness raising text messages
Description: A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
Study: NCT00114894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe Sea ™
Description: Safe Sea ™ applied one time at 2 mg/cm2 coverage

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
Study: NCT01044108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: '2-0453
Description: Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo will be administered as a comparator at each dose level.
Study: NCT02176122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam combination product
Description: Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
Study: NCT02993731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Napabucasin
Description: Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
Study: NCT03429179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: intravenous infusion of the same volume of 0.9% saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: intravenous infusion of the same volume of 0.9% saline
Study: NCT01405963

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered in a 1-hour intravenous infusion
Study: NCT02578329

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual low-fat dietary advice
Description: usual low-fat dietary advice for cardiovascular disease
Study: NCT01044108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo will be administered as a comparator at each dose level.
Study: NCT02993731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
Study: NCT04749303

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Screen
Description: Large screen size is 4x larger than standard screen, we hope that the colonoscopies carried out with large screens will confer to better lesion detection
Study: NCT00620685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, once daily for 4 weeks
Study: NCT01493024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium silicate (ZS)
Description: Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times daily (tid) with meals.
Study: NCT01405963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Administered in a 1-hour intravenous infusion
Study: NCT01493024

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
Study: NCT01333020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cross-linking of an emulsion drink
Description: This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
Study: NCT03908658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle Training and Nasal High Flow
Description: Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Nasal High Flow will support respiratory muscles and thus reduce the work of breathing. By this mechanism the endurance of the respiratory muscles will increase in parallel with the strenght

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training and Venturi mask
Description: Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Venturi mask is usually applied after extubation in every day clinical practice for oxygen supplementation
Study: NCT02441387

Intervention type: DRUG
Intervention: Antidepressant
Description: Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.

Intervention type: DRUG
Intervention: Antidepressant
Description: Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.

Intervention type: OTHER
Intervention: Psychoeducation
Description: Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.

Intervention type: OTHER
Intervention: Treatment as usual (only pharmacological treatment).
Description: Patients who are in the antidepressant treatment group and does not reach remission (MADRS score \<or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
Study: NCT00551681

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biventricular pacemaker with epicardial left ventricular lead
Description: epicardial left ventricular lead placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transvenous left ventricular lead placement
Description: implantation of biventricular pacemaker with transvenous left ventricular lead placement
Study: NCT03436576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Serum 20%
Description: Instillation of 1 drop of Autologous Serum 20% four times a day
Study: NCT00620685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 1 mg PH-797804, once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 5 mg PH-797804, once daily for 4 weeks
Study: NCT03428711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesoglycan Oral Tablet
Description: Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Indistinguible placebo tablet
Study: NCT00180011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: injectable medication
Study: NCT00791596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic Intervention
Description: The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design
Study: NCT02798588

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: 18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)-\>8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition
Study: NCT03438019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrO2
Description: The PrO2 device is linked to a tablet via Bluetooth and provides the user with a graphic representation of their inspiratory effort throughout all of inspiration and real-time biofeedback. This device incorporates a standard 2mm leak to avoid glottal closure during maximal inspiration. The PrO2 provides measures of MIP (cmH2O), SMIP (PTU) and ID (seconds).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Threshold Inspiratory Muscle Trainer
Description: The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold Inspiratory Muscle Trainer
Description: The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
Study: NCT01783886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular Laser Photocoagulation
Description: Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
Study: NCT03046641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous training
Description: Study group I (42 participants) received the continuous training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The interval training
Description: Study group II (40 participants) received the interval training.
Study: NCT03555123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simdax
Description: Levosimendan2.5mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simdax
Description: Levosimendan2.5mg/ml
Study: NCT03305367

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed pine nut oil
Description: Randomized cros-over intervention of 3 OGTT with no oil, low dose or high dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed pine nut oil
Description: Randomized cros-over intervention of 3 OGTT with no oil, low dose or high dose.
Study: NCT04979936

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous cholecystostomy
Study: NCT00685386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Description: The bowel lumen will be insufflated with CO2 during the endoscopy (as compared to room air).
Study: NCT03436576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Serum 50%
Description: Instillation of 1 drop of Autologous Serum 50% four times a day
Study: NCT01234558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13
Description: single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13
Description: single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYX-13
Description: single IV dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLYX-13
Description: single IV dose
Study: NCT02139891

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy with MultiPoint Pacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with MultiPoint Pacing
Study: NCT04237298

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified vacuum-formed retainer covering the palete
Description: The modified vacuum-formed retainer is made where it would cover the hard palate to the second molars. The only difference in constructing this modified VFR when compared to the normal VFR would be the outline which would be trimmed by the technician.
Study: NCT00685386

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room air insufflation
Description: During the ERCP, room air will be insufflated (current standard clinical practice) as a placebo comparator.
Study: NCT04237298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified vacuum-formed retainer covering the palete
Description: The modified vacuum-formed retainer is made where it would cover the hard palate to the second molars. The only difference in constructing this modified VFR when compared to the normal VFR would be the outline which would be trimmed by the technician.
Study: NCT01879046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroplasty
Description: Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
Study: NCT02547168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRhythm ZIO XT patch
Description: The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
Study: NCT01626807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking School Bus
Description: Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
Study: NCT01353417

Intervention type: OTHER
Intervention: In this observational study no study specific intervention is planned
Description: Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
Study: NCT02652468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Fludarabine will be administered by IV over approximately 30 minutes for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV over 24 hours starting prior to cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV for 2 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total nodal irradiation
Description: Undergo total lymphoid irradiation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Description: Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO or IV ONLY if graft cell content is over 1 x 10\^5 cells/kg ideal BW of the patient

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV ONLY if graft B cell content exceeds 1 x 10\^5 cells/kg ideal BW of the patient
Study: NCT03922087

Intervention type: OTHER
Intervention: No intervention
Description: No intervention